PHI has signed a collaboration agreement with the University of Pittsburgh. This agreement makes the fourth with key opinion leaders at leading research institutions and completes the first milestone described in PHI’s offering memorandum.
The collaboration agreement was signed after the research group lead by Professor Jay Kolls evaluated the HoloMonitor® M4 and made important, previously impossible, observations:
“The HoloMonitor® M4’s ability to observe changes in morphology as well as migratory properties in real-time allows us to make observations that we were previously unable to characterize with established methods”, says Dr. Derek Pociask, immunologist at the University of Pittsburgh.
In accordance with the collaboration agreement, University of Pittsburgh will use the HoloMonitor® M4 to track and study individual cell behavior over time. The findings of this groundbreaking research will be published in scientific journals.
“This is a significant achievement of a key milestone that was communicated in the investment memorandum. The next step is to reach the remaining two initial milestones in our strategic plan”, summarizes Peter Egelberg, CEO of PHI.
Since the development of the polio vaccine, University of Pittsburgh is regarded as one of the leading research universities in the world. The university ranks in the very top cluster of U.S. public research universities, according to The Center for Measuring University Performance. Academic Performance Research Laboratory ranks the university as no. 22 in the world among 2 000 colleges and universities for the quality and quantity of its scholarly publications.